Molecular Discovery Grants
Last MDG Cycle: February 2020
The Michigan State University Molecular Discovery Grants (MSU-MDG) have been established between the Department of Pharmacology & Toxicology and MSU Drug Discovery to provide pilot funding for accelerating the discovery and development of chemical technologies with applications for human health, animal health and agricultural use (max $30,000; average: $10,000- 15,000). The primary aim of these funds is to advance projects toward extramural funding or to the creation or development of intellectual property and commercialization.
Specific goals include:
• Assisting investigators in advancing their programs in the early phases of the discovery process with long-term commercialization in mind.
• Supporting early activities (e.g. screening) not readily funded by other sources.
• Providing additional data to support extramural grant applications.
• Aiding in the discovery or development of intellectual property.
• Accelerating therapeutics or diagnostics discovery and development programs
|
MDG Cycle
|
Investigator
|
Title
|
|---|---|---|
| 4 | Jason Bazil, Ph.D. | The search for Novel Mitoprotectants Against Reperfusion Injury |
| Bryan Copple, Ph.D. | Development of Machrphage Phenotypic Modulators as a Treatment for Liver Fibrosis | |
| Sean Crosson, Ph.D. | High Throughput Screening for Host-Directed Antimicrobials Against Intracellular Brucella | |
| Kathleen Gallo, Ph.D. | Mixed Lineage Kinase 3 Inhibitors for Glioblastoma | |
| Jian Hu, Ph.D. | Developing Cell-based High Throughput Screening to Identify Inhibitors Against Pathogenic Fungal ZIP Metal Transporters | |
| Kin Sing Stephen Lee, Ph.D. | Developing a sHE inhibitor with Improved Physicochemical Properties and CNS Penetration for Lupus | |
| Jeffrey MacKeigan, Ph.D | Small Molecule Inhibitors of ULK1 | |
| Aaron Odom, Ph.D. /Jetze Tepe, Ph.D. | Exploration of in vivo Efficacy of Proteasome Inhibitors with Alternative Mechanisms | |
| Bryan Smith, Ph.D. | Marophage-selective Nanotherapy to Treat Breast Cancer | |
| 3 | Robert Abramovitch, Ph.D. | Development of New Mycobacterium tuberculosis MmpL3 Inhibitors |
| Bryan Copple, Ph.D. | Modulation of Macrophage Phenotype to Treat Liver Fibrosis and Cirrhosis | |
| Andrea Doseff, Ph.D. / Karen Liby, Ph.D. | Identifying Novel Strategies for the Treatment of Triple Negative Breast Cancer | |
| Erika Lisabeth, Ph.D. | Identification of Small Molecule Modulators of the Serum Response Factor | |
| Dohun Pyeon, Ph.D. | Developing Chemokine-based Novel Immunotherapies | |
| Christopher Waters, Ph.D. | Identifying Triclosan Analogs That Improve Synergy with Tobramycin to Eradicate Biofilms | |
| 2 | Susan Conrad, Ph.D. | Identifying Novel Strategies for Endocrine-resistant Metastatic ER+ Breast Cancer |
| Aaron Odom, Ph.D. / Jetze Tepe, Ph.D. | Exploration of Viability of Proteasome Inhibitors with Alternative Mechanisms | |
| Chrisopher Waters, Ph.D. | Identifying Compounds That Enhance Biocide Killing of Waters System Biofilms | |
| Stephanie Watts, Ph.D. | 5-HT7 Receptor Drug Discovery for Cardiovascular Disease | |
| Yong-Hui Zheng, Ph.D. | High Throughput Screening of Novel Anti-HIV-1 Compounds | |
| 1 | Robert Abramovitch Ph.D. | Medicinal Chemistry Optimizations of Lead Compounds That Inhibit M. tuberculosis Persistence and drug tolerance |
| Andre Bachmann Ph.D. | Synthesis of Biological Evaluation of Phaseolotoxin-inspired ODC Inhibitors | |
| Jon Kaguni Ph.D. | Targeted Drug Discovery to Identify Inhibitors of Bacterial DNA Replication | |
| Hao-Min Kuo Ph.D. | Hyperphosphorylated tau Aggregation modulators as Candidates for Alzheimer's disease Therapeutics and Risk Factors | |
| Karen Liby, Ph.D. | Synthesis and Characterization of New Rexinoids | |
| Jetze Tepe, Ph.D. | Development of Drug-like TCH-165 Derivatives |
